Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Operating Leases (2019 - 2025)

Enanta Pharmaceuticals filings provide 7 years of Operating Leases readings, the most recent being $53.8 million for Q4 2025.

  • On a quarterly basis, Operating Leases fell 4.73% to $53.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $53.8 million, a 4.73% decrease, with the full-year FY2025 number at $54.8 million, up 1.51% from a year prior.
  • Operating Leases hit $53.8 million in Q4 2025 for Enanta Pharmaceuticals, down from $54.8 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $56.5 million in Q1 2025 to a low of $1.1 million in Q3 2021.
  • Median Operating Leases over the past 5 years was $22.4 million (2022), compared with a mean of $30.6 million.
  • Biggest five-year swings in Operating Leases: plummeted 70.66% in 2021 and later skyrocketed 1886.86% in 2022.
  • Enanta Pharmaceuticals' Operating Leases stood at $16.0 million in 2021, then surged by 36.98% to $21.9 million in 2022, then fell by 6.11% to $20.5 million in 2023, then surged by 175.06% to $56.5 million in 2024, then fell by 4.73% to $53.8 million in 2025.
  • The last three reported values for Operating Leases were $53.8 million (Q4 2025), $54.8 million (Q3 2025), and $55.7 million (Q2 2025) per Business Quant data.